ClearPoint Neuro (CLPT) vs Embecta (EMBC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Embecta (EMBC) has outperformed ClearPoint Neuro (CLPT) over the past year, losing 57.1% versus a loss of 59.6%. Embecta is the larger company by market cap ($334.9 million vs $325.2 million), about 1.0 times the size. Embecta pays a dividend yielding 7.78%, while ClearPoint Neuro does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLPT | EMBC |
|---|---|---|
| Share price | $10.66 | $5.91 |
| Market cap | $325.18M | $334.86M |
| 1-day change | -3.18% | -0.67% |
| YTD return | -22.08% | -50.25% |
| 1-year return | -59.61% | -57.11% |
| 5-year return | -40.65% | — |
| P/E ratio (TTM) | — | 4.02 |
| Forward P/E | — | 3.35 |
| EPS (TTM) | $-1.18 | $1.47 |
| Dividend yield | 0.00% | 7.78% |
| Annual dividend | $0.00 | $0.46 |
| 52-week high | $30.10 | $14.91 |
| 52-week low | $8.27 | $2.77 |
| Distance from 52-week high | -64.58% | -60.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +120.45% | -32.32% |
| Average volume | 639.50K | 1.38M |
| Shares outstanding | 30.50M | 56.66M |
| Employees | 160 | 1,850 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Embecta offers a meaningfully higher dividend yield (7.78% vs 0.00%).
About ClearPoint Neuro
CLPT stock →ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Health Care · Medical/Dental Instruments · 160 employees
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
CLPT vs EMBC FAQ
Which is bigger, ClearPoint Neuro or Embecta?
Embecta (EMBC) is larger, with a market capitalization of $334.86M compared with $325.18M for ClearPoint Neuro (CLPT).
Which stock has performed better over the past year, CLPT or EMBC?
EMBC returned -57.11% over the past 12 months, compared with -59.61% for CLPT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ClearPoint Neuro or Embecta?
Embecta pays a dividend yielding 7.78%, while ClearPoint Neuro does not currently pay a regular dividend.
Are ClearPoint Neuro and Embecta in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.